Nova Eye Medical Limited announced the enrollment of the first glaucoma patient in the Multi-centre Ab-interno Glaucoma study Investigating Canaloplasty trial. MAGIC is a prospective, randomised, single-masked trial across eight surgery centres in the USA and sponsored by Nova Eye Medical. According to the World Health Organisation, glaucoma is the world's second leading cause of blindness, with the number of suspected cases of glaucoma estimated at over 60 million worldwide. The first MAGIC patient was enrolled at the Eye Physicians & Surgeons of Arizona, Arizona, USA, by principal investigator Dr. Shamil Patel, MD. According to Dr. Patel, the unique mechanism of ab- interno canaloplasty, which reduces outflow resistance in all parts of the natural drainage system, recommends its role in the glaucoma treatment armamentarium. Further, the ability to deploy ab-interno canaloplasty as a standalone procedure, and in combination with cataract surgery, supports its versatility in the glaucoma treatment algorithm.